Life Sciences

Lyra Therapeutics Raises $29.5 Million Series B for Chronic Rhinosinusitis

Edward Kim | |

Financing led by Perceptive Advisors to advance ear, nose and throat disease therapies (Image: Lyra Therapeutics).

Verastem Gets its First FDA Approval for Blood Cancer Drug

Edward Kim | |

For relapsed/refractory chronic lymphocytic leukemia, small lymphocytic lymphoma and follicular lymphoma (Image: Verastem)

Ra Medical Systems' $50 Million IPO Expected This Week

Edward Kim | |

Excimer laser system to treat vascular and dermatological diseases (Image: Ra Medical Systems).

uBiome, Owner of Largest Human Microbiome Database, Raises $83 Million Series C Round

Edward Kim | |

Moving into drug discovery and development. Also adds ex Novartis CEO Joseph Jimenez to board (Image: uBiome).

Molecular Templates Signs Cancer Therapy Development Deal with Takeda Worth up to $663 Million

Edward Kim | |

Targeting CD38, a key biomarker in multiple myeloma and other cancers (Image: Molecular Templates).

Galera Therapeutics Secures $150 Million Series C for Oral Mucositis in Cancer Patients

Edward Kim | |

Equity + royalty financing for Phase 3 trial of lead product candidate in Q4 2018 (Image: Galera Therapeutics).

Braeburn Shows Positive Top-Line Phase 3 Data in Chronic Low Back Pain

Edward Kim | |

Weekly and monthly buprenorphine for patients previously on long-term daily opioid therapy (Image: Braeburn)

Y-mAbs Therapeutics' $80 Million IPO Expected This Week for Pediatric Cancer

Edward Kim | |

Two Phase 2 Breakthrough Therapy candidates licensed from Memorial Sloan Kettering (Image: Y-mAbs Therapeutics).

Boehringer Ingelheim Acquires ViraTherapeutics and its Oncolytic Virus Program for $245 Million

Edward Kim | |

Third major acquisition of an oncolytic virus company by Big Pharma this year (Image: UCLA Jonsson Comprehensive Cancer Center).

Principia Biopharma's $75 Million IPO Expected This Week for Small Molecule Drug Discovery

Edward Kim | |

Novel drug discovery platform with programs in immunology, central nervous system disorders and oncology (Image: Principia Biopharma).


Symbol Last Price Change % Change






INTERVIEW: CEO Dr. Martin Eaton - Heads Up Checkup Host & Contributor Silvia Davi interviewing CEO of Heads Up Checkup, Dr. Martin Eaton.